## Renal Osteodystrophy Classification **Key Point:** Secondary hyperparathyroidism with high-turnover bone disease is the most common form of renal osteodystrophy in CKD, accounting for 40–50% of cases. ### Pathophysiology 1. **Phosphate retention** → hyperphosphatemia 2. **Decreased 1,25-dihydroxyvitamin D** production (due to ↓ GFR) 3. **Hypocalcemia** stimulates PTH secretion 4. **Secondary hyperparathyroidism** develops 5. **High bone turnover** with increased osteoblast and osteoclast activity ### Clinical Features of High-Turnover Disease | Feature | Finding | |---------|----------| | **Bone markers** | ↑ ALP, ↑ PTH, ↑ P1NP | | **Bone histology** | Increased osteoid, increased mineralization lag | | **Clinical presentation** | Bone pain, fractures, myopathy | | **Radiography** | Subperiosteal resorption, "rugger jersey spine" | **High-Yield:** The progression from CKD stage 3 onwards involves: - Stage 3: Early PTH elevation - Stage 4: Established secondary hyperparathyroidism - Stage 5: Severe hyperparathyroidism if untreated ### Why High-Turnover in This Patient? The clinical clues are: - **Elevated ALP** → bone turnover marker - **Low-normal calcium** + **elevated phosphate** → classic secondary hyperparathyroidism stimulus - **CKD stage 4** → sufficient renal function loss to impair vitamin D activation **Clinical Pearl:** Bone pain in CKD is a red flag for high-turnover disease and indicates need for aggressive PTH and phosphate management. ### Management Principles 1. **Phosphate binders** (calcium-based or non-calcium) 2. **Active vitamin D** (calcitriol, alfacalcidol) or **vitamin D analogues** (paricalcitol) 3. **Calcimimetics** (cinacalcet) if PTH remains elevated 4. **Dietary phosphate restriction** [cite:Harrison 21e Ch 280]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.